A Functional Genetic Approach Identifies the PI3K Pathway as a Major Determinant of Trastuzumab Resistance in Breast Cancer

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2

Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500

Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets

Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768

Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease

Cobleigh, M., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V. E., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,767

Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer

Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.719 · Cited by 1,860

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients

Nagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.022 · Cited by 1,858

A transforming mutation in the pleckstrin homology domain of AKT1 in cancer

Carpten, J. D., Faber, A. L., Horn, C. L., Donoho, G. P., Briggs, S., Robbins, C. M., Hostetter, G. H., Boguslawski, S. J., Moses, T. Y., Savage, S., et al. (2007) · Nature · doi:10.1038/nature05933 · Cited by 1,322

A large-scale RNAi screen in human cells identifies new components of the p53 pathway

Berns, K., Hijmans, E. M., Mullenders, J., Brummelkamp, T. R., Velds, A., Heimerikx, M., Kerkhoven, R. M., Madiredjo, M., Nijkamp, W., Weigelt, B., et al. (2004) · Nature Cell Biology · doi:10.1038/nature02371 · Cited by 1,080

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

Sergina, N. V., Rausch, M., Wang, D., Blair, J. A., Hann, B. C., Shokat, K. M., & Moasser, M. M. (2007) · Nature · doi:10.1038/nature05474 · Cited by 993

Insulin-Like Growth Factor-I Receptor Signaling and Resistance to Trastuzumab (Herceptin)

Lu, Y., Zi, X., Zhao, Y., Mascarenhas, D. D., & Pollak, M. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.24.1852 · Cited by 886

PIK3CA Mutations Correlate with Hormone Receptors, Node Metastasis, and ERBB2, and Are Mutually Exclusive with PTEN Loss in Human Breast Carcinoma

Saal, L. H., Holm, K., Maurer, M. S., Memeo, L., Su, T., Wang, X., Yu, J. S., Malmström, P.-O., MANSUKHANI, M. M., Enoksson, J., et al. (2005) · Cancer Research · doi:10.1158/0008-5472-can-04-3913 · Cited by 877

Multicenter Phase II Study of Neoadjuvant Lapatinib and Trastuzumab With Hormonal Therapy and Without Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: TBCRC 006

Rimawi, M. F., Mayer, I. A., Forero, A., Nanda, R., Goetz, M. P., Rodriguez, A. A., Pavlick, A. C., Wang, T., Hilsenbeck, S. G., Gutiérrez, C., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.8027 · Cited by 274

Mechanism-based cancer therapy: resistance to therapy, therapy for resistance

Ramos, P. M., & Bentires‐Alj, M. (2014) · Oncogene · doi:10.1038/onc.2014.314 · Cited by 287

Targeting HER2 for the Treatment of Breast Cancer

Rimawi, M. F., Schiff, R., & Osborne, C. K. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-042513-015127 · Cited by 272

BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110α and p110δ Activities in Tumor Cell Lines and Xenograft Models

Liu, N., Rowley, B. R., Bull, C. O., Schneider, C., Haegebarth, A., Schatz, C. A., Fracasso, P. R., Wilkie, D. P., Hentemann, M. F., Wilhelm, S. M., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0993-t · Cited by 263

Targeting the Phosphoinositide-3 (PI3) Kinase Pathway in Breast Cancer

Baselga, J. M. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-s1-12 · Cited by 261

Future of Personalized Medicine in Oncology: A Systems Biology Approach

Gonzalez-Angulo, A. M., Hennessy, B. T., & Mills, G. B. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.0777 · Cited by 262

PIK3CA Mutations Are Associated With Lower Rates of Pathologic Complete Response to Anti–Human Epidermal Growth Factor Receptor 2 (HER2) Therapy in Primary HER2-Overexpressing Breast Cancer

Loibl, S., von Minckwitz, G., Schneeweiß, A., Paepke, S., Lehmann, A., Rezai, M., Zahm, D. M., Sinn, H., Khandan, F., Eidtmann, H., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.7876 · Cited by 258

Molecular profiling of single circulating tumor cells with diagnostic intention

Polzer, B., Medoro, G., Pasch, S., Fontana, F., Zorzino, L., Pestka, A., Andergassen, U., Meier-Stiegen, F., Czyż, Z. T., Alberter, B., et al. (2014) · EMBO Molecular Medicine · doi:10.15252/emmm.201404033 · Cited by 267

Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers

Dave, B., Migliaccio, I., Gutierrez, M. C., Wu, M.-F., Chamness, G. C., Wong, H., Narasanna, A., Chakrabarty, A., Hilsenbeck, S. G., Huang, J., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.7814 · Cited by 252

Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention

Davis, N. M., Sokolosky, M. L., Stadelman, K. M., Abrams, S. L., Libra, M., Candido, S., Nicoletti, F., Polesel, J., Maestro, R., D’Assoro, A. B., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2209 · Cited by 259

PI(3)King Apart PTEN's Role in Cancer

Zhang, S., & Yu, D. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2990 · Cited by 254

Oncogene addiction as a foundational rationale for targeted anti‐cancer therapy: promises and perils

Torti, D., & Trusolino, L. (2011) · EMBO Molecular Medicine · doi:10.1002/emmm.201100176 · Cited by 257

Autophagy Facilitates the Development of Breast Cancer Resistance to the Anti-HER2 Monoclonal Antibody Trastuzumab

Vázquez‐Martín, A., Oliveras‐Ferraros, C., & Menéndez, J. A. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006251 · Cited by 251

Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial

Nakamura, Y., Okamoto, W., Kato, T., Esaki, T., Kato, K., Komatsu, Y., Yuki, S., Masuishi, T., Nishina, T., Ebi, H., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01553-w · Cited by 231

Role of mTOR in anticancer drug resistance: Perspectives for improved drug treatment

Jiang, B., & Liu, L.-Z. (2008) · Drug Resistance Updates · doi:10.1016/j.drup.2008.03.001 · Cited by 249

Heterotrimerization of the Growth Factor Receptors erbB2, erbB3, and Insulin-like Growth Factor-I Receptor in Breast Cancer Cells Resistant to Herceptin

Huang, X., Gao, L., Wang, S., McManaman, J. L., Thor, A. D., Yang, X.-H., Esteva, F. J., & Liu, B. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3321 · Cited by 252

JAK2/STAT5 Inhibition Circumvents Resistance to PI3K/mTOR Blockade: A Rationale for Cotargeting These Pathways in Metastatic Breast Cancer

Britschgi, A., Andraos, R., Brinkhaus, H., Klebba, I., Romanet, V., Müller, U., Murakami, M., Radimerski, T., & Bentires‐Alj, M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.10.023 · Cited by 247

Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives

Vernieri, C., Milano, M., Brambilla, M., Mennitto, A., Maggi, C., Cona, M. S., Prisciandaro, M., Fabbroni, C., Celio, L., Mariani, G., et al. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.05.001 · Cited by 258

Signal Transduction Pathways in Breast Cancer: The Important Role of PI3K/Akt/mTOR

Ortega, M. A., Fraile‐Μartinez, O., Asúnsolo, Á., Buján, J., García‐Honduvilla, N., & Coca, S. (2020) · Journal of Oncology · doi:10.1155/2020/9258396 · Cited by 253

New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer

Yang, S. X., Polley, E. C., & Lipkowitz, S. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.03.004 · Cited by 240

PIK3CA Mutations Are Associated With Decreased Benefit to Neoadjuvant Human Epidermal Growth Factor Receptor 2–Targeted Therapies in Breast Cancer

Majewski, I. J., Nuciforo, P. G., Mittempergher, L., Bosma, A. J., Eidtmann, H., Holmes, E. M., Sotiriou, C. P., Fumagalli, D., Jimenez, J., Aura, C. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.2158 · Cited by 239

Targeting Breast Cancer Metastasis

Jin, X., & Mu, P. (2015) · Breast Cancer Basic and Clinical Research · doi:10.4137/bcbcr.s25460 · Cited by 250

p95HER2 and Breast Cancer

Arribas, J., Baselga, J. M., Pedersen, K., & Parra-Palau, J. L. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3795 · Cited by 241

The PTEN/PI3K/AKT Pathway in vivo, Cancer Mouse Models

Carnero, A., & Paramio, J. M. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00252 · Cited by 241

Structural basis for high-affinity HER2 receptor binding by an engineered protein

Eigenbrot, C. W., Ultsch, M. H., Dubnovitsky, A. P., Abrahmsén, L., & Härd, T. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1005025107 · Cited by 234

Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy

Sierra, J. R., Cepero, V., & Giordano, S. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-75 · Cited by 234

Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines

Kataoka, Y., Mukohara, T., Shimada, H., Saijo, N., Hirai, M., & Minami, H. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp304 · Cited by 234

Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas

Gallardo, A., Lerma, E., Escuín, D., Tibau, A., Muñoz, J., Ojeda, B., Barnadas, A., Adrover, E., Sánchez-Tejada, L., Giner, D., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.85 · Cited by 234

Prognostic significance of PD-L1 and PD-L2 in breast cancer

Baptista, M. Z., Sarian, L. O., Derchain, S., Pinto, G. A., & Vassallo, J. (2015) · Human Pathology · doi:10.1016/j.humpath.2015.09.006 · Cited by 236

PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials

Dey, N., De, P. K., & Leyland-Jones, B. R. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.037 · Cited by 237

Targeting tumour-supportive cellular machineries in anticancer drug development

Dobbelstein, M., & Moll, U. M. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4201 · Cited by 233

Frequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant Breast Cancer

Chandarlapaty, S., Sakr, R. A., Giri, D. D., Patil, S. N., Heguy, A., Morrow, M., Modi, S., Norton, L., Rosen, N. X., Hudis, C. A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1785 · Cited by 228

Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer

Baselga, J. M., Phillips, G. D. L., Verma, S., Ro, J., Huober, J., Guardino, A. E., Samant, M. K., Olsen, S., de Haas, S. L., & Pegram, M. D. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2499 · Cited by 227

Trastuzumab Has Preferential Activity against Breast Cancers Driven by HER2 Homodimers

Ghosh, R., Narasanna, A., Wang, S. E., Liu, S., Chakrabarty, A., Balko, J. M., Gonzalez-Angulo, A. M., Mills, G. B., Penuel, E. M., Winslow, J. W., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1872 · Cited by 233

N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer

Zou, Y., Zheng, S., Xie, X., Ye, F., Hu, X., Tian, Z., Yang, L., Yang, L., Tang, Y., Tang, Y., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30217-7 · Cited by 230

Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo

Barok, M., Tanner, M., Köninki, K., & Isola, J. J. (2011) · Breast Cancer Research · doi:10.1186/bcr2868 · Cited by 226

NF1 Is a Tumor Suppressor in Neuroblastoma that Determines Retinoic Acid Response and Disease Outcome

Hölzel, M., Huang, S., Köster, J., Øra, I., Lakeman, A., Caron, H. N., Nijkamp, W., Xie, J., Callens, T., Asgharzadeh, S., et al. (2010) · Cell · doi:10.1016/j.cell.2010.06.004 · Cited by 225

Maximising the potential of AKT inhibitors as anti-cancer treatments

Brown, J. S., & Banerji, U. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.12.001 · Cited by 222

Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation

Xing, Y., Lin, N., Maurer, M., Chen, H., Mahvash, A., Şahin, A. A., Akçakanat, A., Li, Y., Abramson, V. G., Litton, J. K., et al. (2019) · Breast Cancer Research · doi:10.1186/s13058-019-1154-8 · Cited by 224

Discovery of a Potent, Selective, and Orally Available Class I Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Kinase Inhibitor (GDC-0980) for the Treatment of Cancer

Sutherlin, D. P., Bao, L., Berry, M., Castanedo, G. M., Chuckowree, I., Dotson, J., Folks, A., Friedman, L. S., Goldsmith, R. A., Gunzner, J. L., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2009327 · Cited by 224

PI3K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer

Gonzalez-Angulo, A. M., Ferrer-Lozano, J., Stemke‐Hale, K., Şahin, A. A., Liu, S., Barrera, J. A., Burgués, O., Lluch, A. M., Chen, H., Hortobágyi, G. N., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-1089 · Cited by 219

Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer

Yang, H., Higgins, B., Kolinsky, K., Packman, K., Bradley, W. D., Lee, R. J., Schostack, K., Simcox, M. E., Kopetz, S., Heimbrook, D., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2941 · Cited by 216

PIK3CA mutations in human solid tumors: Role in sensitivity to various therapeutic approaches

Ligresti, G., Militello, L., Steelman, L. S., Cavallaro, A., Basile, F., Nicoletti, F., Stivala, F., McCubrey, J. A., & Libra, M. (2009) · Cell Cycle · doi:10.4161/cc.8.9.8255 · Cited by 214

AKT Inhibitors: New Weapons in the Fight Against Breast Cancer?

Martorana, F., Motta, G., Pavone, G., Motta, L., Stella, S., Vitale, S. R., Manzella, L., & Vigneri, P. G. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.662232 · Cited by 218

PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis

Ilić, N., Utermark, T., Widlund, H. R., & Roberts, T. M. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108237108 · Cited by 217

Resistance to Antibody–Drug Conjugates

García‐Alonso, S., Ocaña, A., & Pandiella, A. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3671 · Cited by 220

Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy

Morrow, P. K., Wulf, G. M., Ensor, J., Booser, D. J., Moore, J. A., Flores, P. R., Xiong, Y., Zhang, S., Krop, I. E., Winer, E. P., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.2321 · Cited by 209

Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib

Broxterman, H. J., Gotink, K. J., & Verheul, H. M. W. (2009) · Drug Resistance Updates · doi:10.1016/j.drup.2009.07.001 · Cited by 209

Drug resistance to targeted therapies: Déjà vu all over again

Groenendijk, F. H., & Bernards, R. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.05.004 · Cited by 222

Elevation of Receptor Tyrosine Kinase EphA2 Mediates Resistance to Trastuzumab Therapy

Zhuang, G., Brantley‐Sieders, D. M., Vaught, D., Yu, J., Xie, L., Wells, S., Jackson, D., Muraoka-Cook, R. S., Arteaga, C. L., & Chen, J. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1845 · Cited by 215

Phase I Study of Everolimus Plus Weekly Paclitaxel and Trastuzumab in Patients With Metastatic Breast Cancer Pretreated With Trastuzumab

André, F., Campone, M., O'Regan, R. M., Manlius, C., Massacesi, C., Tarek, S., Mukhopadhyay, P., Soria, J., Naughton, M., & Hurvitz, S. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.8549 · Cited by 207

Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021

Wu, Q., Qian, W., Sun, X., & Jiang, S. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01362-9 · Cited by 208

Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies

Hanker, A. B., Pfefferle, A. D., Balko, J. M., Kuba, M. G., Young, C. D., Sánchez, V., Sutton, C. R., Cheng, H., Perou, C. M., Zhao, J. J., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303204110 · Cited by 203

Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer

Ruth E. Board, Wardley, A. M., Dixon, J. M., Armstrong, A. C., Howell, S. J., Renshaw, L., Donald, E. L., Greystoke, A., Ranson, M., Hughes, A. M., et al. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0747-9 · Cited by 201

PIK3CA Mutations May Be Discordant between Primary and Corresponding Metastatic Disease in Breast Cancer

Jensen, J. D., Lænkholm, A., Knoop, A. S., Ewertz, M., Bandaru, R., Liu, W., Hackl, W., Barrett, J. C., & Gardner, H. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1133 · Cited by 201

Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer

Gagliato, D. D. M., Jardim, D. L. F., Marchesi, M., & Hortobágyi, G. N. (2016) · Oncotarget · doi:10.18632/oncotarget.7043 · Cited by 204

Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer

Araki, K., & Miyoshi, Y. (2017) · Breast Cancer · doi:10.1007/s12282-017-0812-x · Cited by 201

Mechanisms of Acquired Resistance to Trastuzumab Emtansine in Breast Cancer Cells

Li, G., Guo, J., Shen, B., Yadav, D. B., Sliwkowski, M. X., Crocker, L., Lacap, J. A., & Phillips, G. D. L. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0296 · Cited by 200

Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer

Wang, D., Liu, Z., Lu, Y., Bao, H., Wu, X., Zeng, Z.-L., Liu, Z., Zhao, Q., He, C.-Y., Lu, J., et al. (2018) · Gut · doi:10.1136/gutjnl-2018-316522 · Cited by 196

Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer

She, Q., Gruvberger-Saal, S. K., Maurer, M. S., Chen, Y., Jumppanen, M., Su, T., Dendy, M., Lau, Y.-K. I., Memeo, L., Horlings, H. M., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2609-2 · Cited by 195

Targeted Cancer Therapies in the Twenty-First Century: Lessons From Imatinib

Stegmeier, F. P., Warmuth, M., Sellers, W. R., & Dorsch, M. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.297 · Cited by 196

Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer

Nami, B., Maadi, H., & Wang, Z. (2018) · Cancers · doi:10.3390/cancers10100342 · Cited by 202

PI3K mutations in breast cancer: prognostic and therapeutic implications

Mukohara, T. (2015) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s60696 · Cited by 189

PTEN Tumor-Suppressor: The Dam of Stemness in Cancer

Luongo, F., Colonna, F., Calapà, F., Vitale, S., Fiori, M. E., & Maria, R. D. (2019) · Cancers · doi:10.3390/cancers11081076 · Cited by 200

Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer

Basho, R. K., Gilcrease, M. Z., Murthy, R. K., Helgason, T., Karp, D. D., Meric‐Bernstam, F., Hess, K. R., Herbrich, S. M., Valero, V., Albarracin, C. T., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.5281 · Cited by 188

PIK3CAmutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups

Čížková, M., Susini, A., Vacher, S., Cizeron-Clairac, G., Andrieu, C., Driouch, K., Fourme, E., Lidereau, R., & Bièche, I. (2012) · Breast Cancer Research · doi:10.1186/bcr3113 · Cited by 195

HER2-directed therapy: current treatment options for HER2-positive breast cancer

Ahmed, S., Sami, A., & Xiang, J. (2015) · Breast Cancer · doi:10.1007/s12282-015-0587-x · Cited by 191

Models for prevention and treatment of cancer: Problems vs promises

Aggarwal, B. B., Danda, D., Gupta, S. R., & Gehlot, P. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.05.027 · Cited by 184

Emerging targeted agents in metastatic breast cancer

Zardavas, D., Baselga, J. M., & Piccart, M. J. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.29 · Cited by 184

Simvastatin induces derepression of PTEN expression via NFκB to inhibit breast cancer cell growth

Ghosh-Choudhury, N., Mandal, C. C., Ghosh-Choudhury, N., & Choudhury, G. G. (2010) · Cellular Signalling · doi:10.1016/j.cellsig.2009.12.010 · Cited by 181

Resistance to HER2-directed antibodies and tyrosine kinase inhibitors

Garrett, J. T., & Arteaga, C. L. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.11.9.15045 · Cited by 188

Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer

Razis, E. D., Bobos, M., Kotoula, V., Eleftheraki, A. G., Kalofonos, H. P., Pavlakis, K., Papakostas, P., Aravantinos, G., Rigakos, G., Efstratiou, I., et al. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1572-5 · Cited by 182

Next generation sequencing‐based gene panel tests for the management of solid tumors

Nagahashi, M., Shimada, Y., Ichikawa, H., Kameyama, H., Takabe, K., Okuda, S., & Wakai, T. (2018) · Cancer Science · doi:10.1111/cas.13837 · Cited by 183

HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade

Prat, A., Pascual, T., Angelis, C. D., Gutiérrez, C., Llombart‐Cussac, A., Wang, T., Cortés, J., Rexer, B. N., Paré, L., Forero, A., et al. (2019) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djz042 · Cited by 171

Identification of Subtypes in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer Reveals a Gene Signature Prognostic of Outcome

Staaf, J., Ringnér, M., Vallon‐Christersson, J., Jönsson, G. B., Bendahl, P., Holm, K., Arason, A., Gunnarsson, H., Hegardt, C., Agnarsson, B. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.8775 · Cited by 178

Trastuzumab Mechanism of Action; 20 Years of Research to Unravel a Dilemma

Maadi, H., Soheilifar, M. H., Choi, W.-S., Moshtaghian, A., & Wang, Z. (2021) · Cancers · doi:10.3390/cancers13143540 · Cited by 191

The phosphatidyl inositol 3-kinase/AKT signaling pathway in breast cancer

Castañeda, C. A., Cortés-Funes, H., Gómez, H., & Ciruelos, E. (2010) · Cancer and Metastasis Reviews · doi:10.1007/s10555-010-9261-0 · Cited by 173

Circulating tumour cells and cell-free DNA as tools for managing breast cancer

Mattos‐Arruda, L. D., Cortés, J., Santarpia, L., Vivancos, A. P., Tabernero, J. M., Reis-Filho, J. S., & Seoane, J. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.80 · Cited by 176

Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways

McCubrey, J. A., Steelman, L. S., Kempf, C., Chappell, W. H., Abrams, S. L., Stivala, F., Malaponte, G., Nicoletti, F., Libra, M., Bäsecke, J., et al. (2011) · Journal of Cellular Physiology · doi:10.1002/jcp.22647 · Cited by 177

Antitumor Activity of NVP-BKM120—A Selective Pan Class I PI3 Kinase Inhibitor Showed Differential Forms of Cell Death Based on p53 Status of Glioma Cells

Koul, D., Fu, J., Shen, R., LaFortune, T. A., Wang, S., Tiao, N., Kim, Y., Liu, J.-L., Ramnarian, D., Yuan, Y., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1558 · Cited by 172

Monoclonal antibodies for the treatment of cancer

Shuptrine, C. W., Surana, R., & Weiner, L. M. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2011.12.009 · Cited by 177

High‐throughput screens identify microRNAs essential for HER2 positive breast cancer cell growth

Leivonen, S., Sahlberg, K. K., Mäkelä, R., Due, E. U., Kallioniemi, O., Børresen‐Dale, A., & Perälä, M. (2013) · Molecular Oncology · doi:10.1016/j.molonc.2013.10.001 · Cited by 169

Take your PIK

Ihle, N., & Powis, G. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0801 · Cited by 165

Molecular predictors of response to trastuzumab and lapatinib in breast cancer

Esteva, F. J., Yu, D., Hung, M., & Hortobágyi, G. N. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.216 · Cited by 170

Genome profiling of ERBB2-amplified breast cancers

Sircoulomb, F., Bekhouche, I., Finetti, P., Adélaı̈de, J., Hamida, A. B., Bonansea, J., Raynaud, S., Innocenti, C., Charafe‐Jauffret, E., Tarpin, C., et al. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-539 · Cited by 166

Pertuzumab: new hope for patients with HER2-positive breast cancer

Capelán, M., Pugliano, L., de Azambuja, E., Bozovic, I., Saini, K. S., Sotiriou, C. P., Loi, S., & Piccart, M. J. (2012) · Annals of Oncology · doi:10.1093/annonc/mds328 · Cited by 174

Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response

de Ronde, J. J., Hannemann, J., Halfwerk, H., Mulder, L., Straver, M. E., Peeters, M.-J. T. F. D. V., Wesseling, J., van de Vijver, M. J., Wessels, L. F. A., & Rodenhuis, S. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0499-6 · Cited by 167

Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2–Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3

André, F., Hurvitz, S. A., Fasolo, A., Tseng, L., Jérusalem, G., Wilks, S. T., O'Regan, R. M., Isaacs, C. J., Toi, M., Burris, H. A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.9161 · Cited by 167

Transforming Growth Factor β Engages TACE and ErbB3 To Activate Phosphatidylinositol-3 Kinase/Akt in ErbB2-Overexpressing Breast Cancer and Desensitizes Cells to Trastuzumab

Wang, S. E., Xiang, B., Guix, M., Olivares, M. G., Parker, J. S., Chung, C. H., Pandiella, A., & Arteaga, C. L. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00787-08 · Cited by 168

Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer

Canonici, A., Gijsen, M., Mullooly, M., Bennett, R., Bouguern, N., Pedersen, K., O’Brien, N. A., Roxanis, I., Li, J., Bridge, E., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.1148 · Cited by 164

Mechanisms of Acquired Resistance to Targeted Cancer Therapies

Lackner, M. R., Wilson, T. R., & Settleman, J. (2012) · Future Oncology · doi:10.2217/fon.12.86 · Cited by 167

KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer

Krall, E. B., Wang, B., Munoz, D. M., Ilic, N., Raghavan, S., Niederst, M. J., Yu, K., Ruddy, D. A., Aguirre, A. J., Kim, J. W., et al. (2017) · eLife · doi:10.7554/elife.18970 · Cited by 160

In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer

Janiszewska, M., Liu, L., Almendro, V., Kuang, Y., Paweletz, C. P., Sakr, R. A., Weigelt, B., Hanker, A. B., Chandarlapaty, S., King, T. A., et al. (2015) · Nature Genetics · doi:10.1038/ng.3391 · Cited by 163

Functions and Regulation of the PTEN Gene in Colorectal Cancer

Molinari, F., & Frattini, M. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2013.00326 · Cited by 171

Pathway-Based Identification of Biomarkers for Targeted Therapeutics: Personalized Oncology with PI3K Pathway Inhibitors

Andersen, J. N., Sathyanarayanan, S., Bacco, A. D., Chi, A., Zhang, T., Chen, A. H., Dolinski, B. M., Kraus, M., Roberts, B. S., Arthur, W. T., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001065 · Cited by 164

Management of breast cancer with targeted agents: importance of heterogenicity

Cosimo, S. D., & Baselga, J. M. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.234 · Cited by 159

Mechanisms of Resistance to Antibody-Drug Conjugates

Khoury, R., Saleh, K., Khalife, N., Saleh, M. A., Chahine, C., Ibrahim, R., & Cesne, A. L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119674 · Cited by 174

Functional Identification of Tumor-Suppressor Genes through an In Vivo RNA Interference Screen in a Mouse Lymphoma Model

Bric, A., Miething, C., Bialucha, C. U., Scuoppo, C., Zender, L., Krasnitz, A., Xuan, Z., Zuber, J. A., Wigler, M. H., Hicks, J. B., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.08.015 · Cited by 162

Systems biology approaches for advancing the discovery of effective drug combinations

Ryall, K. A., & Tan, A. C. (2015) · Journal of Cheminformatics · doi:10.1186/s13321-015-0055-9 · Cited by 160

Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2–Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial

Sonnenblick, A., Agbor‐Tarh, D., Bradbury, I., Cosimo, S. D., Azim, H. A., Fumagalli, D., Sarp, S., Wolff, A. C., Andersson, M., Kroep, J. R., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.7722 · Cited by 161

PTEN, PIK3CA, p-AKT, and p-p70S6K Status

Esteva, F. J., Guo, H., Zhang, S., Santa-Maria, C., Stone, S., Lanchbury, J. S., Sahin, A. A., Hortobagyi, G. N., & Yu, D. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.090885 · Cited by 285

PI3 Kinase Activation and Response to Trastuzumab Therapy: What's neu with Herceptin Resistance?

Park, B. H., & Davidson, N. E. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.10.004 · Cited by 47

An Integrative Analysis of PIK3CA Mutation, PTEN, and INPP4B Expression in Terms of Trastuzumab Efficacy in HER2-Positive Breast Cancer

Sueta, A., Yamamoto, Y., Yamamoto‐Ibusuki, M., Hayashi, M., Takeshita, T., Yamamoto, S., & Iwase, H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0116054 · Cited by 30

An evaluation of PI3K pathway activation on the efficacy of both trastuzumab and lapatinib.

Hu, X., Wang, L. P., Zhang, Q. L., Zhang, J., Guo, H., Sun, S., Wang, B. Y., Jia, Z., Shao, Z. M., & Wang, Z. H. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.541

Abstract P3-07-11: High activation of PI3K pathway defined by PIK3CA mutation, PTEN, and INPP4B expression are associated with trastuzumab efficacy in HER2-positive breast cancer

Sueta, A., Yamamoto, Y., Takeshita, T., Yamamoto‐Ibusuki, M., & Iwase, H. (2016) · Cancer Research · doi:10.1158/1538-7445.sabcs15-p3-07-11